West Pharmaceutical Services (WST) Enterprise Value (2009 - 2026)

West Pharmaceutical Services (WST) has reported Enterprise Value for 18 consecutive years, with -$435.8 million the latest figure, recorded in Q2 2026.

• Quarterly Enterprise Value rose 14.5% year-over-year to -$435.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$435.8 million (up 14.5% YoY) and the FY2025 annual result came in at -$791.3 million, down 63.29% from the prior year.
• Enterprise Value rose to -$435.8 million in Q2 2026 per WST's latest filing, from -$521.4 million in the prior quarter.
• Over the last five years, Enterprise Value for WST reached as high as -$404.2 million in Q1 2025 and fell as low as -$898.6 million in Q3 2023.
• A 5-year average of -$653.3 million and a median of -$648.1 million in 2022 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value jumped 45.37% — and 2025, when it slumped 63.29%.
• Year by year, Enterprise Value stood at -$894.3 million in 2022, then rose by 4.52% to -$853.9 million in 2023, then soared by 43.25% to -$484.6 million in 2024, then sank by 63.29% to -$791.3 million in 2025, then jumped by 44.93% to -$435.8 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$435.8 million, -$521.4 million, and -$791.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.